BIIB (Biogen) Cyclically Adjusted Revenue per Share: $75.49 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIIB Biogen Inc BIIB
72 GF Score
Price $216.17
GF Value $196.25
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Biogen Cyclically Adjusted Revenue per Share?

Biogen BIIB -0.55% 72 Cyclically Adjusted Revenue per Share is $75.49 as of Jun. 2026. GuruFocus rates BIIB with a GF Score™ of 72/100 and a GF Value™ of $196.25 (Fairly Valued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biogen's adjusted revenue per share for the three months ended in Jun. 2026 was $17.636. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $75.49 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Biogen's average Cyclically Adjusted Revenue Growth Rate was 3.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 13.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biogen was 53.80% per year. The lowest was 5.10% per year. And the median was 21.20% per year.

As of today (2026-09-16), Biogen's current stock price is $216.17. Biogen's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $75.49. Biogen's Cyclically Adjusted PS Ratio of today is 2.86.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biogen was 10.97. The lowest was 1.45. And the median was 4.76.


Biogen  (NAS:BIIB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biogen's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=216.17/75.487
=2.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biogen was 10.97. The lowest was 1.45. And the median was 4.76.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biogen Cyclically Adjusted Revenue per Share Related Terms


Biogen Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Biogen's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Cyclically Adjusted Revenue per Share Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.49 62.07 67.38 70.81 73.67

Biogen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.67 73.42 73.01 74.50 75.49

BIIB vs OGN, AMRN, NSRX: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted PS Ratio falls into.


BIIB
72GF Score
Biogen Inc BIIB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogen's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=17.636/333.9520*333.9520
=17.636

Current CPI (Jun. 2026) = 333.9520.

Biogen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 12.124 241.428 16.770
201612 13.207 241.432 18.268
201703 11.489 243.801 15.737
201706 12.855 244.955 17.525
201709 13.085 246.819 17.704
201712 14.204 246.524 19.241
201803 13.299 249.554 17.797
201806 14.472 251.989 19.179
201809 15.300 252.439 20.240
201812 15.718 251.233 20.893
201903 15.637 254.202 20.543
201906 16.838 256.143 21.953
201909 17.214 256.759 22.389
201912 18.275 256.974 23.749
202003 18.236 258.115 23.594
202006 21.144 257.797 27.390
202009 19.840 260.280 25.456
202012 6.044 260.474 7.749
202103 16.374 264.877 20.644
202106 17.506 271.696 21.517
202109 17.824 274.310 21.699
202112 17.492 278.802 20.952
202203 16.085 287.504 18.684
202206 16.453 296.311 18.543
202209 15.836 296.808 17.818
202212 17.172 296.797 19.322
202303 16.056 301.836 17.764
202306 16.158 305.109 17.685
202309 16.818 307.789 18.248
202312 15.782 306.746 17.182
202403 15.081 312.332 16.125
202406 16.127 314.175 17.142
202409 16.261 315.301 17.223
202412 16.000 315.605 16.930
202503 15.935 319.799 16.640
202506 17.461 322.561 18.078
202509 16.688 324.800 17.158
202512 14.866 324.054 15.320
202603 16.195 330.213 16.378
202606 17.636 333.952 17.636

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $75.49 mean?
Biogen (BIIB) has a Cyclically Adjusted Revenue per Share of $75.49 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biogen and its competitors.
Is Biogen's Cyclically Adjusted Revenue per Share too high?
Biogen's current Cyclically Adjusted Revenue per Share is $75.49. Overall, Biogen has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biogen's Cyclically Adjusted Revenue per Share compare to OGN and AMRN?
Biogen's Cyclically Adjusted Revenue per Share of $75.49 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biogen and its competitors. Biogen's current Cyclically Adjusted Revenue per Share is $75.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (BIIB) is currently considered Fairly Valued. The stock's GF Value™ is $196.25, compared to a current price of $216.17 — trading 10.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $75.49. Biogen's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Biogen (BIIB), the current Cyclically Adjusted Revenue per Share is $75.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogen (BIIB) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of $216.17 is trading 10.2% above its estimated GF Value™ of $196.25. GuruFocus considers Biogen to be Fairly Valued.

Key valuation signals for BIIB:

  • Cyclically Adjusted Revenue per Share: $75.49
  • GF Value™: $196.25 vs. price of $216.17 (10.2% above fair value)
  • GF Score™: 72/100 with 10 warning signs

No single metric tells the full story. See the BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
72GF Score

Get the complete analysis for BIIB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$216.17
Price
$196.25
GF Value